Saving changes...

Done

Error

Oncology Pharmacy Consults: Updates on the Management of Prostate Cancer

Oncology Pharmacy Consults: Updates on the Management of Prostate Cancer

Oncology Pharmacy Consults: Updates on the Management of Prostate Cancer

J. Aubrey  Waddell, PharmD, FAPhA, BCOP
J. Aubrey Waddell, PharmD, FAPhA, BCOP
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172111

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Prostate cancer (PC) is the leading cause of cancer among men in the United States, and androgen deprivation therapy (ADT) strategies that reduce serum testosterone to castrate levels have been shown to improve survival and other outcomes. However, almost all men with advanced PC eventually progress to castrate-resistant PC and sometimes to metastatic castrate-resistant PC (mCRPC). Recent research has identified new approaches to improve survival and other outcomes for patients with mCRPC, including androgen-blocking drugs, cytotoxic chemotherapy regimens, immunotherapy approaches and radiopharmaceuticals that target skeletal metastases. This enduring case-based activity will provide participants with up-to-date information regarding selecting an appropriate management plan for patients with PC taking into consideration a number of factors including treatment history, symptom severity, and skeletal complications, as well as the unique safety and tolerability issues associated with each approach. It will also highlight the pharmacist's critical role in working with other healthcare professionals to select optimal treatment strategies for patients with mCRPC, identify and manage adverse events (AEs), ensure appropriate monitoring and evaluation, and provide patient education.

Objectives

Objectives
At the conclusion of this activity, the participant should be able to:

-Assess the efficacy of current and emerging therapy options for PC in various patient subtypes.
-Evaluate the role of immunotherapy in PC treatment.
-Identify strategies to mitigate AEs related to prostate cancer and its treatment, including skeletal, cardio-metabolic and renal AEs.
J. Aubrey  Waddell, PharmD, FAPhA, BCOP

Author Information Play Video Bio

J. Aubrey Waddell, PharmD, FAPhA, BCOP
on behalf of Postgraduate Healthcare Education, LLC

J. Aubrey Waddell, PharmD, FAPhA, BCOP (Chair) Professor University of Tennessee College of Pharmacy Knoxville, Tennessee

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 0.50 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-223-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error